Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China
· Delayed Price · Currency is CNY 30.74
+0.24 (0.79%)
Mar 10, 2026, 10:15 AM CST
SHA:688319 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 12,374 | 10,294 | 4,303 | 6,417 | 5,621 | 14,513 | Upgrade
|
| Market Cap Growth | 167.16% | 139.25% | -32.95% | 14.17% | -61.27% | - | Upgrade
|
| Enterprise Value | 12,562 | 10,482 | 4,422 | 6,267 | 5,420 | 14,115 | Upgrade
|
| Last Close Price | 30.50 | 25.36 | 10.60 | 15.74 | 13.81 | 35.67 | Upgrade
|
| PE Ratio | 556.60 | 463.05 | 207.29 | 365.54 | 211.50 | 134.42 | Upgrade
|
| Forward PE | 210.34 | 131.33 | 98.61 | 60.77 | 38.44 | 59.68 | Upgrade
|
| PS Ratio | 17.57 | 14.62 | 7.31 | 12.94 | 10.27 | 29.79 | Upgrade
|
| PB Ratio | 12.78 | 10.63 | 4.61 | 6.90 | 6.30 | 17.18 | Upgrade
|
| P/TBV Ratio | 13.13 | 10.92 | 4.74 | 7.13 | 6.51 | 17.47 | Upgrade
|
| P/OCF Ratio | - | - | - | 145.85 | - | 363.16 | Upgrade
|
| EV/Sales Ratio | 17.84 | 14.89 | 7.51 | 12.63 | 9.90 | 28.97 | Upgrade
|
| EV/EBITDA Ratio | 213.60 | 178.24 | 89.21 | 204.71 | 135.49 | 120.71 | Upgrade
|
| EV/EBIT Ratio | - | 339.71 | 204.54 | 1787.91 | 368.70 | 150.33 | Upgrade
|
| Debt / Equity Ratio | 0.41 | 0.41 | 0.39 | 0.26 | 0.15 | 0.05 | Upgrade
|
| Debt / EBITDA Ratio | 6.75 | 6.75 | 6.79 | 6.93 | 3.35 | 0.33 | Upgrade
|
| Net Debt / Equity Ratio | 0.19 | 0.19 | 0.13 | -0.13 | -0.25 | -0.49 | Upgrade
|
| Net Debt / EBITDA Ratio | 3.05 | 3.05 | 2.42 | -4.07 | -5.63 | -3.56 | Upgrade
|
| Net Debt / FCF Ratio | - | - | -0.55 | 0.99 | 1.00 | 13.99 | Upgrade
|
| Asset Turnover | - | - | 0.34 | 0.32 | 0.41 | 0.53 | Upgrade
|
| Inventory Turnover | - | - | 0.38 | 0.49 | 0.56 | 0.47 | Upgrade
|
| Quick Ratio | - | - | 1.37 | 1.80 | 1.63 | 2.34 | Upgrade
|
| Current Ratio | - | - | 1.53 | 1.96 | 1.78 | 2.56 | Upgrade
|
| Return on Equity (ROE) | 2.34% | 2.34% | 1.69% | 1.26% | 3.06% | 17.68% | Upgrade
|
| Return on Assets (ROA) | - | - | 0.79% | 0.14% | 0.68% | 6.33% | Upgrade
|
| Return on Invested Capital (ROIC) | 1.87% | 1.95% | 1.64% | 0.35% | 1.63% | 26.12% | Upgrade
|
| Return on Capital Employed (ROCE) | - | - | 1.80% | 0.30% | 1.50% | 10.80% | Upgrade
|
| Earnings Yield | 0.18% | 0.22% | 0.48% | 0.27% | 0.47% | 0.74% | Upgrade
|
| FCF Yield | - | - | -5.04% | -1.96% | -4.01% | -0.21% | Upgrade
|
| Dividend Yield | - | - | - | 0.24% | - | - | Upgrade
|
| Payout Ratio | - | - | 142.97% | 34.11% | 16.00% | 0.95% | Upgrade
|
| Buyback Yield / Dilution | -0.07% | -0.07% | 0.01% | -0.07% | -5.22% | -5.61% | Upgrade
|
| Total Shareholder Return | -0.07% | -0.07% | 0.01% | 0.17% | -5.22% | -5.61% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.